Levels of circulating CD45 dim CD34 VEGFR2 progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors

British Journal of Cancer

Volumn 104, Issue 7, 2011, Pages 1144-1150

  Farace, F ^a,b   Gross Goupil, M ^a   Tournay, E ^a   Taylor, M ^a,b   Vimond, N ^a   Jacques, N ^a   Billiot, F ^a   Mauguen, A ^a   Hill, C ^a   Escudier, B ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Universite Paris Sud   (France)

Author keywords

angiogenesis; biomarker; circulating endothelial cells; circulating endothelial progenitor cells; metastatic renal cell carcinoma; tyrosine kinase inhibitors

Indexed keywords

ANGIOGENIC FACTOR; SORAFENIB; STROMAL CELL DERIVED FACTOR 1ALPHA; SUNITINIB; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTIGENS, CD45; CARCINOMA, RENAL CELL; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79953183344     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.72     Document Type: Article

References (30)

1. Asahara T, Takahashi T, Masuda H, Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM (1999) VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18(14): 3964-3972 (Pubitemid 29335849)
2. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1): 83-95 (Pubitemid 46075199)
3. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8): 592-603
4. Blann AD, Woywodt A, Bertolini F, Bull TM, Buyon JP, Clancy RM, Haubitz M, Hebbel RP, Lip GY, Mancuso P, Sampol J, Solovey A, Dignat-George F (2005) Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 93(2): 228-235 (Pubitemid 40253726)
5. Deprimo SE, Bello CL, Smeraglia JBaum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5: 32-43
6. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS (2007) Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104(43): 17069-17074 (Pubitemid 350210993)
7. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2): 125-134 (Pubitemid 46089673)
8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27(20): 3312-3318
9. Farace F, Massard C, Borghi E (2007) Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells. Ann Oncol 18(8): 1421-1422 (Pubitemid 47305018)
10. Gao D, Nolan DJ, Mellick AS, Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V (2008) Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319(5860): 195-198
11. Goon PK, Lip GYGoon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD, Boos CJ (2006) Circulating endothelial cells, endothelial progenitor cells and endothelial microparticles in cancer. Neoplasia 8(2): 79-88
12. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B (2000) Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 63(1): 343-347
13. Jacques N, Vimond N, Conforti R, Griscelli F, Lecluse Y, Laplanche A, Malka D, Vielh P, Farace F (2008) Quantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assay. J Immunol Methods 337: 132-143
14. Jubb AM, Oates AJ, Holden S, Holden S, Koeppen H (2006) Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 6(8): 626-635 (Pubitemid 44140860)
15. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438(7069): 820-827 (Pubitemid 41753060)
16. Lyden D, Hattori K, Dias S Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7(11): 1194-1201 (Pubitemid 33063774)
17. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9(1): 327-337 (Pubitemid 36109749)
18. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2): 115-124 (Pubitemid 46089672)
19. Nolan DJ, Ciarrocchi A, Mellick AS, Nolan DJ, Ciarrocchi A, Mellick AS, Jaggi JS, Bambino K, Gupta S, Heikamp E, McDevitt MR, Scheinberg DA, Benezra R, Mittal V (2007) Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 21(12): 1546-1558 (Pubitemid 46955726)
20. Peters BA, Diaz LA, Polyak K, Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, Antin JH, Myerson D, Hamilton SR, Vogelstein B, Kinzler KW, Lengauer C (2005) Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 11(3): 261-262 (Pubitemid 40460552)
21. Purhonen S, Palm J, Rossi D, Kaskenpää N, Rajantie I, Ylä-Herttuala S, Alitalo K, Weissman IL, Salven P (2008) Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci USA 105(18): 6620-6625 (Pubitemid 351754556)
22. Rini BI, Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23(5): 1028-1043 (Pubitemid 46202321)
23. Shaked Y, Ciarrocchi A, Franco M, Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313(5794): 1785-1787 (Pubitemid 44454154)
24. Spring H, Schüler T, Arnold B, Hämmerling GJ, Ganss R (2005) Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci USA 102(50): 18111-18116 (Pubitemid 41798510)
25. Strijbos MH, Gratama JW, Kraan J, Lamers CH, den Bakker MA, Sleijfer S (2008) Circulating endothelial cells in oncology: pitfalls and promises. Br J Cancer 98(11): 1731-1735 (Pubitemid 351748848)
26. Taylor M, Rössler J, Geoerger B, Laplanche A, Hartmann O, Vassal G, Farace F (2009) High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies. Clin Cancer Res 15(14): 4561-4571
27. Vroling L, Lind JS, de Haas RR, Verheul HM, Van Hinsbergh VW, Broxterman HJ, Smit EF (2010) CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. Br J Cancer 102(2): 268-275
28. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19): 7099-7109 (Pubitemid 39331023)
29. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10(2): 145-147 (Pubitemid 38524883)
30. Yoder MC, Ingram DA (2009) Endothelial progenitor cell: ongoing controversy for defining these cells and their role in neoangiogenesis in the murine system. Curr Opin Hematol 16(4): 269-273